NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Can we expect publication before May 10th?

The process outlined in the Company’s October 5, 2020 announcement relating to the Phase III trial of DCVax-L is continuing to move forward. The process includes review and analysis of the raw data by independent statisticians and experts, and preparation of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts in preparation for public announcement and scientific publication.

The Company continues to be in a quiet period while this process is under way. The Company appreciates shareholders’ patience, and their understanding that the Company cannot make partial disclosures during this process and cannot comment on the Phase III trial schedule or its data until the announcement of the results. We remain committed to completing the full plan outlined on October 5, 2020.

"The Company"...."cannot comment on Phase III...data until the announcement of the results".

Is Linda Liau a part of the "company"? Per Dr. Liau's March 31st disclosures:

Thursday, March 31, 2022
LL’s presentation -Therapy-induced resistance in glioblastoma: New Concepts.
________________________________________
LL’s Disclosures:

° Research grants/funding to institution:

- NIH
- Northwest Biotherapetucis

I'd imagine if you are being paid by NWBO you fall under the NWBO 'Company' umbrella.

Revisiting the prior PRs, "the Company...cannot comment on Phase III...data until the announcement of results." It appears the announcement of results could happen March 10th, per this press release:

NWBO

BETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
This presentation can be viewed virtually by registering online at the Academy's website at­­­ https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary

Going back to the original game plan for NWBO, public announcement would be concurrent with "scientific publication".

I think it is reasonable to think we might have a publication before 5-10-22. The only question is whether Dr. Liau is considered part of "the Company". I'm also assuming she is speaking on new P3 info, which I think is a safe assumption from today's NWBO PR in addition to the NYAS email.

Potentially exciting times ahead.